BeStock  
Stocks › Biotechnology › DSGN

Design Therapeutics DSGN

US equityMarket cap rank #3474Biotechnology
$11.69 −$0.28 (-2.34%)
Pre-market · Oct 8, 8:20 am ET · After hours $11.69 0.00%
Open$11.82
Prev close$11.97
Day range$11.58 – $12.06
Volume344.5K
Market cap$731.58M
P/E (TTM)–
Dividend yield–

Earnings

QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q128 Apr 2026After Market±38.3%+23.26%Within range
2023/Q419 Mar 2024After Market–+11.97%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Fundamentals

Full statements →

Latest reported quarter: Q2, ended Jun 2026

Revenue$0.00
Operating profit-$22.18M-2.8% YoY
Net profit-$20.17M-5.7% YoY
Diluted EPS-$0.32+5.9% YoY
Free cash flow-$15.55M-7.0% YoY
Operating cash flow-$15.52M

Revenue, last 8 quarters

$0.0Sep '24$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26

Net profit, last 8 quarters

$-13.0MSep '24$-13.7MDec '24$-17.7MMar '25$-19.1MJun '25$-17.0MSep '25$-16.0MDec '25$-17.6MMar '26$-20.2MJun '26

Profitability & balance sheet

Return on equity-34.1%
Return on assets-32.3%
Return on invested capital-37.8%
Current ratio18.86
Liabilities / assets6.2%
Cash & investments$207.40M
Total debt$2.03M
Net cash (debt)$205.37M

Discussion

No comments yet — be the first to weigh in on DSGN.

Leave a comment

Scroll to Top